In this randomized clinical trial of adults with obesity and NAFLD, a TRE regimen did not achieve additional benefits for reducing IHTG content, weight, body fat, and metabolic risk factors compared with DCR, whereas TRE might be more effective in improving insulin sensitivity than DCR. The gene discussed is INS; the disease is obesity disorder.